Pharmacokinetic interactions of antidepressants

Elliott Richelson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Seven of the newest antidepressants are the serotonin selective reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine [currently approved in the United States for obsessive-compulsive disorder only]), a serotonin norepinephrine reuptake inhibitor (venlafaxine), a postsynaptic serotonin antagonist/presynaptic serotonin reuptake inhibitor (nefazodone), and presynaptic/postsynaptic noradrenergic/serotonergic receptor antagonist (mirtazapine). Many of these drugs are potent inhibitors of the cytochrome P450 (CYP) enzymes of the liver. The CYP enzymes most relevant to the use of antidepressants and for which the most thorough data are available are the CYP1A2, CYP2D6, and CYP3A4. These 3 CYP isoenzymes are discussed in relation to some of the drugs they metabolize, and appropriate cautions are recommended for concurrent administration of these new antidepressants and other drugs frequently prescribed to elderly patients.

Original languageEnglish (US)
Pages (from-to)22-26
Number of pages5
JournalJournal of Clinical Psychiatry
Volume59
Issue numberSUPPL. 10
StatePublished - 1998

Fingerprint

Cytochrome P-450 Enzyme System
Antidepressive Agents
Pharmacokinetics
Serotonin Uptake Inhibitors
Fluvoxamine
Sertraline
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP1A2
Cytochrome P-450 CYP2D6
Paroxetine
Serotonin Antagonists
Fluoxetine
Obsessive-Compulsive Disorder
Pharmaceutical Preparations
Isoenzymes
Liver

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Pharmacokinetic interactions of antidepressants. / Richelson, Elliott.

In: Journal of Clinical Psychiatry, Vol. 59, No. SUPPL. 10, 1998, p. 22-26.

Research output: Contribution to journalArticle

Richelson, E 1998, 'Pharmacokinetic interactions of antidepressants', Journal of Clinical Psychiatry, vol. 59, no. SUPPL. 10, pp. 22-26.
Richelson, Elliott. / Pharmacokinetic interactions of antidepressants. In: Journal of Clinical Psychiatry. 1998 ; Vol. 59, No. SUPPL. 10. pp. 22-26.
@article{8f955fab3be64dc39faae83fb8bd16e5,
title = "Pharmacokinetic interactions of antidepressants",
abstract = "Seven of the newest antidepressants are the serotonin selective reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine [currently approved in the United States for obsessive-compulsive disorder only]), a serotonin norepinephrine reuptake inhibitor (venlafaxine), a postsynaptic serotonin antagonist/presynaptic serotonin reuptake inhibitor (nefazodone), and presynaptic/postsynaptic noradrenergic/serotonergic receptor antagonist (mirtazapine). Many of these drugs are potent inhibitors of the cytochrome P450 (CYP) enzymes of the liver. The CYP enzymes most relevant to the use of antidepressants and for which the most thorough data are available are the CYP1A2, CYP2D6, and CYP3A4. These 3 CYP isoenzymes are discussed in relation to some of the drugs they metabolize, and appropriate cautions are recommended for concurrent administration of these new antidepressants and other drugs frequently prescribed to elderly patients.",
author = "Elliott Richelson",
year = "1998",
language = "English (US)",
volume = "59",
pages = "22--26",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 10",

}

TY - JOUR

T1 - Pharmacokinetic interactions of antidepressants

AU - Richelson, Elliott

PY - 1998

Y1 - 1998

N2 - Seven of the newest antidepressants are the serotonin selective reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine [currently approved in the United States for obsessive-compulsive disorder only]), a serotonin norepinephrine reuptake inhibitor (venlafaxine), a postsynaptic serotonin antagonist/presynaptic serotonin reuptake inhibitor (nefazodone), and presynaptic/postsynaptic noradrenergic/serotonergic receptor antagonist (mirtazapine). Many of these drugs are potent inhibitors of the cytochrome P450 (CYP) enzymes of the liver. The CYP enzymes most relevant to the use of antidepressants and for which the most thorough data are available are the CYP1A2, CYP2D6, and CYP3A4. These 3 CYP isoenzymes are discussed in relation to some of the drugs they metabolize, and appropriate cautions are recommended for concurrent administration of these new antidepressants and other drugs frequently prescribed to elderly patients.

AB - Seven of the newest antidepressants are the serotonin selective reuptake inhibitors (fluoxetine, sertraline, paroxetine, and fluvoxamine [currently approved in the United States for obsessive-compulsive disorder only]), a serotonin norepinephrine reuptake inhibitor (venlafaxine), a postsynaptic serotonin antagonist/presynaptic serotonin reuptake inhibitor (nefazodone), and presynaptic/postsynaptic noradrenergic/serotonergic receptor antagonist (mirtazapine). Many of these drugs are potent inhibitors of the cytochrome P450 (CYP) enzymes of the liver. The CYP enzymes most relevant to the use of antidepressants and for which the most thorough data are available are the CYP1A2, CYP2D6, and CYP3A4. These 3 CYP isoenzymes are discussed in relation to some of the drugs they metabolize, and appropriate cautions are recommended for concurrent administration of these new antidepressants and other drugs frequently prescribed to elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=0031812945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031812945&partnerID=8YFLogxK

M3 - Article

C2 - 9720479

AN - SCOPUS:0031812945

VL - 59

SP - 22

EP - 26

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 10

ER -